

Special Issue

WAMD: From Pathophysiology to Therapeutic Treatment 2.0

Message from the Guest Editors

In this Special Issue on wet age-related macular degeneration (wAMD), we would like to explore new wAMD strategies to achieve better visual acuity and retina structural outcomes. Age-related macular degeneration is one of the main causes of visual impairment in elderly people. While the dry form has no approved treatment, several therapies have been proposed for the wAMD form to try to change the course of the disease and to improve visual acuity. The main treatments for wAMD are based on targeting choroidal neovascular membranes. The anti-VEGF agents have dramatically improved the disease outcome. In this issue, we are especially interested in examining consolidated and new anti-VEGF therapies and also considering the treatment protocols. Potential topics will include:

- Aflibercept, ranibizumab and brolucizumab treatment regimen
- Clinical trials for new drugs development
- Different types of wAMD and related disease outcomes
- Possible application of telemedicine in wAMD diagnosis and follow-up
- Nutritional supplements in wAMD

Guest Editors

Dr. Francesca Toja

Dr. Stefano Lupo

Dr. Enzo Maria Vingolo

Deadline for manuscript submissions

closed (31 August 2023)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/137186

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLUS / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).